scholarly journals Rapidly progressing programmed cell death 1 inhibitor‐related pneumonitis in a hemodialytic patient with metastatic renal cell carcinoma

2019 ◽  
Vol 2 (3) ◽  
pp. 155-157
Author(s):  
Yoshiaki Matsumura ◽  
Yusuke Iemura ◽  
Shinji Fukui ◽  
Yoshihiro Tatsumi ◽  
Yoriaki Kagebayashi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Programmed Cell Death 1

scholarly journals Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma

2020 ◽  
Vol 3 (5) ◽  
pp. 176-179 ◽  
Author(s):  
Yoko Maegawa ◽  
Taigo Kato ◽  
Shinichiro Fukuhara ◽  
Hiroshi Kiuchi ◽  
Ryoichi Imamura ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Experienced Patient ◽  
Programmed Cell Death 1

Atezolizumab-induced type 1 diabetes mellitus in a patient with metastatic renal cell carcinoma

2020 ◽  
Vol 13 (7) ◽  
pp. e233842 ◽  
Author(s):  
Wedad Rahman ◽  
Anna Conley ◽  
Kristi D Silver
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Death ◽  
Type 1 Diabetes ◽  
Programmed Cell Death ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Checkpoint Inhibitor ◽  
Autoimmune Reaction

Checkpoint inhibitor immunotherapy has revolutionised cancer treatment since its inception. During an inflammatory response, activated cytotoxic T cells expressing programmed cell death protein 1 (PD-1) interact with programmed cell death-ligand 1 (PD-L1) on peripheral tissues to thwart an autoimmune reaction. Cancer cells upregulate PD-L1 expression to evade the immune system and are vulnerable to attack in the presence of PD-1 or PD-L1 checkpoint inhibitors. However, blockade of this pathway also contributes to the unintended side effect of autoimmune endocrinopathies. Atezolizumab, a checkpoint inhibitor against PD-L1, is associated with the rare complication of type 1 diabetes. We present a case of glutamic acid decarboxylase antibody-positive type 1 diabetes developing in a patient with a long-standing history of well-controlled type 2 diabetes following treatment with atezolizumab for metastatic renal cell carcinoma.

scholarly journals Programmed cell death ligand 1 and tumor‐infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation

Cancer ◽  
2017 ◽  
Vol 123 (24) ◽  
pp. 4823-4831 ◽  
Author(s):  
Fumi Kawakami ◽  
Kanishka Sircar ◽  
Jaime Rodriguez‐Canales ◽  
Bryan M. Fellman ◽  
Diana L. Urbauer ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Tumor Infiltrating Lymphocyte
Sign in / Sign up

Export Citation Format

Share Document